Summary of Clinical Use

Xeligekimab (GR-1501) is in clinical studies to determine safety and efficacy as a treatment for chronic inflammatory diseases, including plaque psoriasis, axial spondyloarthritis and lupus nephritis. It was first approved by the China NMPA in August 2024 [1]. Xeligekimab (Jinlixi®) is indicated to treat moderate to severe plaque psoriasis.

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT05162937	to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis	Phase 2 Interventional	Genrix (Shanghai) Biopharmaceutical Co., Ltd.
NCT05881785	Study of Efficacy and Safety of GR1501 in Patients with Radiographic Axial Spondyloarthritis	Phase 3 Interventional	Genrix (Shanghai) Biopharmaceutical Co., Ltd.
NCT06802848	Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)	Observational	Chongqing Genrix Biopharmaceutical Co., Ltd